Jonathan Allan - 15 Mar 2026 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Mar 2026, 17:23:45 UTC
Prior SEC filing
19 Feb 2026
Next SEC filing
19 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan Allan

Key filing fact

Jonathan Allan filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 17 Mar 2026.

Key facts

  • This page summarizes Jonathan Allan's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
  • 6 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 17 Mar 2026, 17:23.

Change

  • Previous filing in this sequence was filed on 19 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001966716 Primary reporting owner

Allan Jonathan

Relationship
GENERAL COUNSEL & CORP SEC
Address
C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD
Signature
/s/ Jonathan Allan
Signature date
17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STOK transaction

Common Stock

Options Exercise

Transaction value
Shares
+7,475
Change %
+61%
Price
$0.000000*
Shares after
19,731
Date
15 Mar 2026
Ownership
Direct
Footnotes
F1
STOK transaction

Common Stock

Options Exercise

Transaction value
Shares
+6,000
Change %
+30%
Price
$0.000000*
Shares after
25,731
Date
15 Mar 2026
Ownership
Direct
STOK transaction

Common Stock

Options Exercise

Transaction value
Shares
+12,000
Change %
+47%
Price
$0.000000*
Shares after
37,731
Date
15 Mar 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STOK transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-7,475
Change %
-50%
Price
$0.000000*
Shares after
7,475
Date
15 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,475
Exercise price
Footnotes
F2, F3
STOK transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-6,000
Change %
-33%
Price
$0.000000*
Shares after
12,000
Date
15 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
6,000
Exercise price
Footnotes
F2, F4
STOK transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-12,000
Change %
-25%
Price
$0.000000*
Shares after
36,000
Date
15 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,000
Exercise price
Footnotes
F2, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The reported total includes an aggregate 425 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

Footnote F3

The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.

Footnote F4

The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.

Footnote F5

The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .